BACKGROUND: In vitro studies in mantle cell lymphoma (MCL) cell lines and patient-derived cells have demonstrated synergistic apoptosis with combined rituximab and bortezomib (R-bortezomib) compared with single-agent bortezomib. Therefore, the authors of this report evaluated R-bortezomib in a preclinical model and in a phase 2 clinical trial. METHODS: A Hu-MCL-severe combined immunodeficiency (SCID) model engrafted with the Jeko cell line was treated with R-bortezomib, bortezomib, or rituximab. Twenty-five patients with relapsed follicular lymphoma (n = 11) and MCL (n = 14) received 375 mg/m(2) rituximab on Days 1 and 8 and 1.3 to 1.5 mg/m(2) bortezomib on Days 1, 4, 8, and 11 every 21 days for a median of 3 cycles (range, 1-5 cycles). RESULTS: R-bortezomib resulted in a statistically significant improvement in overall survival in Hu-MCL-SCID mice. In the clinical trial, the overall response rate was 40% in all 25 patients, 55% in patients with follicular lymphoma, and 29% in patients with MCL. The estimated 2-year progression-free survival (PFS) rate was 24% (95% confidence interval [CI], 10%-53%) in all patients and 60% (95% CI, 20%-85%) in responding patients. Thirteen patients (52%) developed grade 3 neurotoxicity, which consisted of constipation/ileus, sensory or motor neuropathy, or orthostatic hypotension. Patients who were heterozygous for the CD32a (Fcγ receptor IIa) 131 histidine (H) to arginine (R) polymorphism had a significantly decreased PFS (P = .009) after R-bortezomib compared with HH and RR homozygotes. CONCLUSIONS: R-bortezomib had significant activity in patients with relapsed or refractory follicular lymphoma and MCL, although an unexpectedly high incidence of grade 3 neurologic toxicity was a potential limiting factor with this combination.
BACKGROUND: In vitro studies in mantle cell lymphoma (MCL) cell lines and patient-derived cells have demonstrated synergistic apoptosis with combined rituximab and bortezomib (R-bortezomib) compared with single-agent bortezomib. Therefore, the authors of this report evaluated R-bortezomib in a preclinical model and in a phase 2 clinical trial. METHODS: A Hu-MCL-severe combined immunodeficiency (SCID) model engrafted with the Jeko cell line was treated with R-bortezomib, bortezomib, or rituximab. Twenty-five patients with relapsed follicular lymphoma (n = 11) and MCL (n = 14) received 375 mg/m(2) rituximab on Days 1 and 8 and 1.3 to 1.5 mg/m(2) bortezomib on Days 1, 4, 8, and 11 every 21 days for a median of 3 cycles (range, 1-5 cycles). RESULTS:R-bortezomib resulted in a statistically significant improvement in overall survival in Hu-MCL-SCIDmice. In the clinical trial, the overall response rate was 40% in all 25 patients, 55% in patients with follicular lymphoma, and 29% in patients with MCL. The estimated 2-year progression-free survival (PFS) rate was 24% (95% confidence interval [CI], 10%-53%) in all patients and 60% (95% CI, 20%-85%) in responding patients. Thirteen patients (52%) developed grade 3 neurotoxicity, which consisted of constipation/ileus, sensory or motor neuropathy, or orthostatic hypotension. Patients who were heterozygous for the CD32a (Fcγ receptor IIa) 131 histidine (H) to arginine (R) polymorphism had a significantly decreased PFS (P = .009) after R-bortezomib compared with HH and RR homozygotes. CONCLUSIONS:R-bortezomib had significant activity in patients with relapsed or refractory follicular lymphoma and MCL, although an unexpectedly high incidence of grade 3 neurologic toxicity was a potential limiting factor with this combination.
Authors: Robert Z Orlowski; Thomas E Stinchcombe; Beverly S Mitchell; Thomas C Shea; Albert S Baldwin; Stephanie Stahl; Julian Adams; Dixie-Lee Esseltine; Peter J Elliott; Christine S Pien; Roberto Guerciolini; Jessica K Anderson; Natalie D Depcik-Smith; Rita Bhagat; Mary Jo Lehman; Steven C Novick; Owen A O'Connor; Steven L Soignet Journal: J Clin Oncol Date: 2002-11-15 Impact factor: 44.544
Authors: A Goy; S H Bernstein; B S Kahl; B Djulbegovic; M J Robertson; S de Vos; E Epner; A Krishnan; J P Leonard; S Lonial; S Nasta; O A O'Connor; H Shi; A L Boral; R I Fisher Journal: Ann Oncol Date: 2008-12-12 Impact factor: 32.976
Authors: Carol Aghajanian; Steven Soignet; Don S Dizon; Christine S Pien; Julian Adams; Peter J Elliott; Paul Sabbatini; Vincent Miller; Martee L Hensley; Sandra Pezzulli; Christina Canales; Adil Daud; David R Spriggs Journal: Clin Cancer Res Date: 2002-08 Impact factor: 12.531
Authors: S Jagannath; B Barlogie; J Berenson; D Siegel; D Irwin; P G Richardson; R Niesvizky; R Alexanian; S A Limentani; M Alsina; J Adams; M Kauffman; D-L Esseltine; D P Schenkein; K C Anderson Journal: Br J Haematol Date: 2004-10 Impact factor: 6.998
Authors: Philippe Solal-Céligny; Pascal Roy; Philippe Colombat; Josephine White; Jim O Armitage; Reyes Arranz-Saez; Wing Y Au; Monica Bellei; Pauline Brice; Dolores Caballero; Bertrand Coiffier; Eulogio Conde-Garcia; Chantal Doyen; Massimo Federico; Richard I Fisher; Javier F Garcia-Conde; Cesare Guglielmi; Anton Hagenbeek; Corinne Haïoun; Michael LeBlanc; Andrew T Lister; Armando Lopez-Guillermo; Peter McLaughlin; Noël Milpied; Pierre Morel; Nicolas Mounier; Stephen J Proctor; Ama Rohatiner; Paul Smith; Pierre Soubeyran; Hervé Tilly; Umberto Vitolo; Pier-Luigi Zinzani; Emanuele Zucca; Emili Montserrat Journal: Blood Date: 2004-05-04 Impact factor: 22.113
Authors: Paul G Richardson; Bart Barlogie; James Berenson; Seema Singhal; Sundar Jagannath; David Irwin; S Vincent Rajkumar; Gordan Srkalovic; Melissa Alsina; Raymond Alexanian; David Siegel; Robert Z Orlowski; David Kuter; Steven A Limentani; Stephanie Lee; Teru Hideshima; Dixie-Lee Esseltine; Michael Kauffman; Julian Adams; David P Schenkein; Kenneth C Anderson Journal: N Engl J Med Date: 2003-06-26 Impact factor: 91.245
Authors: Wolfgang Lamm; Hannes Kaufmann; Markus Raderer; Martha Hoffmann; Andreas Chott; Christoph Zielinski; Johannes Drach Journal: Haematologica Date: 2011-04-12 Impact factor: 9.941
Authors: Mahadeo A Sukhai; Swayam Prabha; Rose Hurren; Angela C Rutledge; Anna Y Lee; Shrivani Sriskanthadevan; Hong Sun; Xiaoming Wang; Marko Skrtic; Ayesh Seneviratne; Maria Cusimano; Bozhena Jhas; Marcela Gronda; Neil MacLean; Eunice E Cho; Paul A Spagnuolo; Sumaiya Sharmeen; Marinella Gebbia; Malene Urbanus; Kolja Eppert; Dilan Dissanayake; Alexia Jonet; Alexandra Dassonville-Klimpt; Xiaoming Li; Alessandro Datti; Pamela S Ohashi; Jeff Wrana; Ian Rogers; Pascal Sonnet; William Y Ellis; Seth J Corey; Connie Eaves; Mark D Minden; Jean C Y Wang; John E Dick; Corey Nislow; Guri Giaever; Aaron D Schimmer Journal: J Clin Invest Date: 2012-12-03 Impact factor: 14.808
Authors: Jonathon B Cohen; Jeffrey M Switchenko; Jean L Koff; Rajni Sinha; Jonathan L Kaufman; H Jean Khoury; Nassoma Bumpers; Amanda Colbert; Amanda Hutchison-Rzepka; Loretta J Nastoupil; Leonard T Heffner; Amelia A Langston; Mary Jo Lechowicz; Sagar Lonial; Christopher R Flowers Journal: Br J Haematol Date: 2015-08-07 Impact factor: 6.998
Authors: Andrew D Zelenetz; Leo I Gordon; William G Wierda; Jeremy S Abramson; Ranjana H Advani; C Babis Andreadis; Nancy Bartlett; John C Byrd; Myron S Czuczman; Luis E Fayad; Richard I Fisher; Martha J Glenn; Nancy Lee Harris; Richard T Hoppe; Steven M Horwitz; Christopher R Kelsey; Youn H Kim; Susan Krivacic; Ann S LaCasce; Auayporn Nademanee; Pierluigi Porcu; Oliver Press; Rachel Rabinovitch; Nishitha Reddy; Erin Reid; Ayman A Saad; Lubomir Sokol; Lode J Swinnen; Christina Tsien; Julie M Vose; Joachim Yahalom; Nadeem Zafar; Mary Dwyer; Hema Sundar Journal: J Natl Compr Canc Netw Date: 2014-09 Impact factor: 11.908